SEC 13F Intelligence

Managers / Q1 2022 · view latest →

FRAZIER MANAGEMENT LLC

CIK 0001032165 · 601 UNION ST, SUITE 2110, SEATTLE, WA, 98101 · 2066217200

Reported Value
Under review
reported total failed a data-quality check
Positions
2
Filings on Record
15
2019–present window
Filed
May 13, 2022
original filing

Summary

Compared with Q4 2021, the fund opened 0 new positions and exited 41.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $415MQ1 ’19Q2 ’19: $390MQ3 ’19: $320MQ3 ’19Q4 ’19: $596MQ1 ’20: $882MQ1 ’20Q2 ’20: $1.1BQ3 ’20: $1.1BQ3 ’20Q4 ’20: $1.3BQ1 ’21: $1.2BQ1 ’21Q2 ’21: $1.1BQ3 ’21: $1.2BQ3 ’21Q4 ’21: $1.3BQ2 ’22: $1MQ2 ’22Q3 ’22: $0filingsflow.com

Portfolio Composition

By security type
Other: 88.1%Common Stock: 11.9%
  • Other · 88.1% · $2M
  • Common Stock · 11.9% · $236,000

Quarter-over-Quarter Changes full breakdown →

vs Q4 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ARQTARCUTIS BIOTHERAPEUTICS INCSOLD OUT−8.43M0−$175M$0
PHATPHATHOM PHARMACEUTICALS INCSOLD OUT−5.83M0−$115M$0
IMAGO BIOSCIENCES INCSOLD OUT−2.97M0−$70M$0
SNDXSYNDAX PHARMACEUTICALS INCSOLD OUT−2.77M0−$61M$0
GRITSTONE BIO INCSOLD OUT−4.67M0−$60M$0
MIRMMIRUM PHARMACEUTICALS INCSOLD OUT−3.57M0−$57M$0
PCVXVAXCYTE INCSOLD OUT−2.31M0−$55M$0
KRYSKRYSTAL BIOTECH INCSOLD OUT−771.3K0−$54M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2022

2 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SIERRA ONCOLOGY INCCOM NEW88.13%$2M54.7K
2ALLENA PHARMACEUTICALSCOM11.87%$236,0001.02M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$01Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1M1Aug 10, 202213F-HRchanges · EDGAR ↗
Q1 2022Under review2May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.3B43Feb 8, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B41Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.1B34Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.2B35May 12, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.3B35Feb 11, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.1B31Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B26Aug 4, 202013F-HRchanges · EDGAR ↗
Q1 2020$882M25May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$596M20Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$320M19Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$390M18Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$415M17May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.